Strategic market Leverage the early-stage high technology medical device position to target research institutions and hospitals seeking innovative local drug delivery solutions for difficult-to-treat brain cancers and leptomeningeal carcinomatosis.

High impact product Focus on prospective buyers for the Metronomic Biofeedback Pump as a disruptive implantable infusion system capable of remotely programmable, metronomic chemotherapy delivery, highlighting potential for personalized treatment regimens and improved local efficacy.

Intellectual assets Highlight patented and development-stage technologies such as VEGF BioSensor and Intelligent Interbody Fusion Device to position cross-sell opportunities in neuro-oncology diagnostics, spinal surgery augmentation, and adjunctive therapies.

Strategic partnerships Pursue collaborations with biomedical research centers, clinical trial networks, and contract research organizations to validate efficacy, accelerate regulatory pathways, and create early adoption cases for local drug delivery and biosensing capabilities.

Funding and pilots Leverage current revenue and modest funding to propose pilot programs with select hospitals and academic centers, emphasizing proof-of-concept studies, real-world data collection, and phased procurement for the MBP and related SDDS technologies.